Daily Respiratory Research Analysis
Three advances span prevention, diagnosis, and treatment of respiratory disease: (1) a TROP2-directed antibody–drug conjugate (sacituzumab tirumotecan) shows robust activity in previously treated EGFR-mutant NSCLC; (2) thin-section low-dose CT reconstruction combined with AI detects more early-stage lung cancers in non-high-risk individuals; and (3) an intranasal replicon SARS-CoV-2 vaccine induces mucosal immunity and blocks transmission in animals.
Summary
Three advances span prevention, diagnosis, and treatment of respiratory disease: (1) a TROP2-directed antibody–drug conjugate (sacituzumab tirumotecan) shows robust activity in previously treated EGFR-mutant NSCLC; (2) thin-section low-dose CT reconstruction combined with AI detects more early-stage lung cancers in non-high-risk individuals; and (3) an intranasal replicon SARS-CoV-2 vaccine induces mucosal immunity and blocks transmission in animals.
Research Themes
- Targeted therapeutics in EGFR-mutant NSCLC (TROP2 ADC)
- AI-augmented thin-section LDCT screening in non-high-risk populations
- Intranasal replicon vaccination for mucosal immunity and transmission blocking
Selected Articles
1. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
In two prospective trials, sacituzumab tirumotecan achieved notable responses in previously treated NSCLC, with superior activity in EGFR-mutant disease (ORR up to 55%, median PFS up to 11.1 months). Safety was manageable, dominated by hematologic events, and exploratory data suggested enhanced ADC internalization in EGFR-mutant cells.
Impact: This therapy may address an unmet need in EGFR-mutant NSCLC after resistance to TKIs, a population with limited options, and could redirect development of TROP2-ADCs after prior trial failures.
Clinical Implications: If confirmed in phase 3, sac-TMT could become a targeted option post-TKI in EGFR-mutant NSCLC. Clinicians should monitor for hematologic toxicity and remain vigilant for rare ILD.
Key Findings
- Confirmed ORR 40% and median PFS 6.2 months in KL264-01 (n=43).
- EGFR-mutant subset achieved ORR 55% and median PFS 11.1 months.
- Independent phase 2 (SKB264-II-08) in EGFR-mutant NSCLC showed ORR 34% and median PFS 9.3 months (n=64).
- Hematologic toxicities were most common; diarrhea (4%) and ILD (1%) were uncommon.
- EGFR mutation increased in vitro internalization/activity of sac-TMT.
Methodological Strengths
- Two prospective multicenter trials with concordant efficacy signals.
- Mechanistic exploration linking EGFR status to ADC internalization.
Limitations
- Nonrandomized design; comparative effectiveness versus current standards is unknown.
- Sample sizes remain modest; longer-term survival and safety data are pending.
Future Directions: Complete ongoing randomized phase 3 trials in EGFR-mutant NSCLC; define biomarkers (e.g., TROP2 expression, EGFR context) and resistance mechanisms; assess sequencing with TKIs and combination strategies.
Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC. Here we report the efficacy and safety of sac-TMT in previously treated, advanced NSCLC with or without activating EGFR mutations from the phase 1/2 KL264-01 and phase 2 SKB264-II-08 studies. Primary endpoint was objective response rate (ORR). KL264-01 enrolled EGFR-wild-type and EGFR-mutant NSCLC (n = 43). Confirmed ORR was 40% (17 of 43; 95% confidence interval (CI), 25-56). Median progression-free survival (PFS) was 6.2 months (95% CI, 5.3-11.3). Post-hoc subgroup analyses found better outcomes in the EGFR-mutant subset (22 of 43, 51%) with a confirmed ORR of 55% (12 of 22) and median PFS of 11.1 months. These findings were independently supported by results from SKB264-II-08, where sac-TMT led to confirmed ORR of 34% (22 of 64; 95% CI, 23-47) and median PFS of 9.3 months (95% CI, 7.6-11.4) in 64 patients with EGFR-mutant NSCLC. For a total of 107 patients receiving sac-TMT, the most common treatment-related adverse events were hematologic toxicities. Diarrhea (4%) and interstitial lung disease (1%) were uncommon. Exploration of potential mechanisms revealed that the presence of EGFR mutation substantially increased the internalization and activity of sac-TMT in vitro. Overall, sac-TMT showed encouraging single-agent activity and manageable tolerability in previously treated, advanced NSCLC with EGFR mutations. Randomized phase 3 trials in treatment-naive and previously treated patients with EGFR-mutant NSCLC are ongoing. ClinicalTrials.gov Identifiers: NCT04152499 , NCT05631262 .
2. Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.
An intranasal replicon vaccine delivered via nanostructured lipid carriers induced robust mucosal (lung-resident memory T cells) and systemic immunity. In hamsters, both intranasal and intramuscular routes reduced viral loads and disease, and notably, vaccination prevented transmission to naive cage-mates.
Impact: Establishes a platform for mucosal vaccination that could close the gap in upper-airway protection and transmission blocking, a major limitation of current systemic COVID-19 vaccines.
Clinical Implications: Supports development of intranasal boosters to augment mucosal immunity after prior intramuscular vaccination; informs trial design focused on transmission endpoints.
Key Findings
- Intranasal vaccination induced robust lung-resident memory T cells alongside systemic neutralizing antibodies.
- Both intranasal and intramuscular administration protected hamsters, reducing viral loads and disease.
- Vaccinated, challenged hamsters did not transmit virus to naive cagemates.
- Intranasal boosting after prior intramuscular vaccination elicited mucosal virus-specific T cells.
Methodological Strengths
- Head-to-head comparison of intranasal vs intramuscular routes with immunologic phenotyping (including tissue-resident T cells).
- Transmission assessment in a controlled animal model with clear endpoints (viral load, morbidity, transmission).
Limitations
- Preclinical animal model; human immunogenicity, durability, and safety remain to be established.
- Variant breadth and correlates of protection for transmission in humans are not yet defined.
Future Directions: Advance to human trials assessing mucosal immunity, safety, and transmission endpoints; evaluate heterologous boosting, dose optimization, and breadth across respiratory pathogens.
While mRNA vaccines have been effective in combating SARS-CoV-2, the waning of vaccine-induced antibody responses and lack of vaccine-induced respiratory tract immunity contribute to ongoing infection and transmission. In this work, we compare and contrast intranasal (i.n.) and intramuscular (i.m.) administration of a SARS-CoV-2 replicon vaccine delivered by a nanostructured lipid carrier (NLC). Both i.m. and i.n. vaccines induce potent systemic serum neutralizing antibodies, bone marrow-resident immunoglobulin G-secreting cells, and splenic T cell responses. The i.n. vaccine additionally induces robust respiratory mucosal immune responses, including SARS-CoV-2-reactive lung-resident memory T cell populations. As a booster following previous i.m. vaccination, the i.n. vaccine also elicits the development of mucosal virus-specific T cells. Both the i.m.- and i.n.-administered vaccines durably protect hamsters from infection-associated morbidity upon viral challenge, significantly reducing viral loads and preventing challenged hamsters from transmitting virus to naive cagemates. This replicon-NLC vaccine's potent systemic immunogenicity, and additional mucosal immunogenicity when delivered i.n., may be key for combating SARS-CoV-2 and other respiratory pathogens.
3. Early-stage lung cancer detection via thin-section low-dose CT reconstruction combined with AI in non-high risk populations: a large-scale real-world retrospective cohort study.
In 259,121 non-high-risk individuals, AI-augmented thin-section LDCT detected more lung cancers than traditional LDCT, with 92.7% of cases at stage I and 87.1% in never-smokers. The findings support extending screening beyond classic high-risk criteria and highlight the value of thin-section reconstruction plus AI triage.
Impact: This large real-world study challenges current screening boundaries by demonstrating clinical yield in non-high-risk populations, particularly never-smokers, and shows how AI with thin-section LDCT can improve early detection.
Clinical Implications: Health systems should consider piloting AI-augmented thin-section LDCT programs in non-high-risk cohorts while evaluating cost-effectiveness and overdiagnosis; radiology workflows may benefit from AI triage.
Key Findings
- Among 259,121 non-high-risk participants, 0.3% were diagnosed with lung cancer within 1 year; 92.7% were stage I.
- 87.1% of detected cancers occurred in never-smokers.
- LDCT-TRAI achieved a higher cancer detection rate than traditional LDCT (0.3% vs 0.2%).
- AI system (uAI-ChestCare) applied to thin-section reconstructions enhanced screening performance.
Methodological Strengths
- Very large real-world cohort with pathology confirmation of diagnoses.
- Direct comparative analysis between AI-augmented thin-section LDCT and traditional LDCT.
Limitations
- Retrospective design susceptible to selection and information biases.
- Limited detail on false positives, downstream procedures, and formal cost-effectiveness/overdiagnosis metrics.
Future Directions: Prospective pragmatic trials to assess mortality impact, cost-effectiveness, and overdiagnosis; refine AI thresholds across demographics; integrate risk models beyond smoking history.
BACKGROUND: Current lung cancer screening guidelines recommend annual low-dose computed tomography (LDCT) for high-risk individuals. However, the effectiveness of LDCT in non-high-risk individuals remains inadequately explored. With the incidence of lung cancer steadily increasing among non-high-risk individuals, this study aims to assess the risk of lung cancer in non-high-risk individuals and evaluate the potential of thin-section LDCT reconstruction combined with artificial intelligence (LDCT-TRAI) as a screening tool. METHODS: A real-world cohort study on lung cancer screening was conducted at the West China Hospital of Sichuan University from January 2010 to July 2021. Participants were screened using either LDCT-TRAI or traditional thick-section LDCT without AI (traditional LDCT) . The AI system employed was the uAI-ChestCare software. Lung cancer diagnoses were confirmed through pathological examination. RESULTS: Among the 259 121 enrolled non-high-risk participants, 87 260 (33.7%) had positive screening results. Within 1 year, 728 (0.3%) participants were diagnosed with lung cancer, of whom 87.1% (634/728) were never-smokers, and 92.7% (675/728) presented with stage I disease. Compared with traditional LDCT, LDCT-TRAI demonstrated a higher lung cancer detection rate (0.3% vs. 0.2%, CONCLUSION: These findings highlight the importance of expanding lung cancer screening to non-high-risk populations, especially never-smokers. LDCT-TRAI outperformed traditional LDCT in detecting early-stage cancers and improving survival outcomes, underscoring its potential as a more effective screening tool for early lung cancer detection in this population.